Meriofert

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed to stimulate follicular development and ovulation in women undergoing fertility treatment.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used in reproductive medicine to support ovarian function and ovulation.

- Infertility (female): promotes follicular growth and ovulation to improve chances of conception. - Assisted Reproductive Technology (ART): enhances ovarian response during controlled ovarian stimulation protocols. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH/LH to induce ovulation in women with hormonal insufficiency.

Adverse reactions may occur with any injectable gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal discomfort or bloating: transient gastrointestinal symptoms. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid ovarian enlargement with fluid shifts. - Thromboembolic events: rare clot formation. - Allergic reactions or anaphylaxis: signs of severe hypersensitivity. - Multiple pregnancy: increased risk of twins or higher order gestations. - Ectopic pregnancy: rare but serious implantation outside the uterus.

Careful monitoring and patient selection are essential when using Meriofert.

- Assess ovarian response: perform serial ultrasound to track follicle development. - Screen for contraindications: avoid in active malignancy or uncontrolled thyroid disease. - Review cardiovascular risk: use caution in patients with thrombotic history. - Monitor hormone levels: adjust dosing based on serum estradiol and LH measurements. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other agents that affect ovarian stimulation or hemostasis.

Major Interactions (Avoid): - GnRH agonists: can amplify response, increasing risk of severe ovarian hyperstimulation. - Oral contraceptives: may blunt the ovulatory effect of FSH/LH. - Thyroid hormone therapy: may require dose adjustment to maintain euthyroid status.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk if ovarian cyst rupture occurs. - Insulin or oral hypoglycemics: monitor glucose control during ovarian hyperstimulation episodes.